Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail

NCT00453271 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 443

Last updated 2013-05-23

No results posted yet for this study

Summary

The purpose of the study is to determine whether NB002, 0.25%, and 0.5% are safe and effective in the treatment of distal subungual onychomycosis of the toenail.

Conditions

  • Onychomycosis

Interventions

DRUG

NB-002

DRUG

Vehicle control

Sponsors & Collaborators

  • NanoBio Corporation

    lead INDUSTRY

Principal Investigators

  • Alicia Barba, MD · International Dermatology Research, Inc.

  • Alicia Bucko, DO · Academic Dermatology Associates

  • Richard Pollak, DPM, MS · Endeavor Clinical Trials, PA

  • Michael Jarratt, MD · Derm Research, PLLC

  • Terry Jones, MD · J & S Studies, Inc.

  • Robert Kaylor, DPM · Welborne Clinic

  • Steven Kempers, MD · Minnesota Clinical Study Center

  • Robert Matheson, MD · Oregon Medical Research Center, PC

  • Brock McConnehey,, DO · Northwest Clinical Trial

  • David Pariser, MD · Virginia Clinical Research, Inc.

  • Phoebe Rich, MD · Oregon Dermatology and Research Center

  • Dan Stewart, DO · Michigan Center for Research Corp

  • Leonard Swinyer, MD · Dermatology Research Center, Inc.

  • Robert Bissonette, MD · Innovaderm Research Inc.

  • Sylvia Garnis-Jones, MD · EntraLogix Clinical Group Inc.

  • David Gratton, MD · International Dermatology Research, Inc.

  • Lyn Guenther, MD · The Guenther Dermatology Research Centre

  • Rod Kunynetz, MD · Ultranova Skincare

  • Charles Lynde, MD · Lynderm Research, Inc.

  • Richard Langley, MD · Eastern Canada Cutaneous Research Associates, LTD

  • Kim Papp, MD · K. Papp Clinical Research

  • Yves Poulin, MD · Centre de Reeberche Dermatologique du Quebec Metropolitain (CRDQ)

  • Wayne Gulliver, MD · Newlab Clinical Research Inc.

  • R G Sibbald, MD · Dermatology Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00453271 on ClinicalTrials.gov